HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Matrix metalloprotease expressions in both reperfusion lung injury and oleic acid lung injury models and the protective effects of ilomastat.

AbstractOBJECTIVE:
Our aim was to study the expressions of matrix metalloprotease 9 (MMP9) and the effects of the MMP inhibitor Ilomastat in both ischemia/reperfusion (I/R)- and oleic acid (OA)-induced lung injury models.
MATERIALS AND METHODS:
Real-time polymerase chain reactions and Western blots were used to assess mRNA and protein expressions of MMP9 in lung tissues after I/R or OA lung injury. Ischemia was induced by clamping one branch of the pulmonary artery for 60 minutes and then reperfusing for 120 minutes. In the OA model, lung injury was induced by intravenous infusion of OA (0.1 mL/kg) for 20 minutes and then observation for 6 hours. Lavage leukocyte concentration and wet/dry lung weight ratio were used to assess lung inflammation and injury. Blood samples were collected for assays of hydroxyl radicals and nitric oxide. The MMP inhibitor Ilomastat (100 microg/kg) was administered before I/R and OA infusion.
RESULTS:
mRNA and protein expressions of MMP9 were significantly increased in both lung injury models. Ilomastat decreased MMP9 mRNA and protein expressions but did not reach statistical significance. Blood concentrations of hydroxyl radicals and nitric oxide, wet/dry lung weight ratios, and lavage leukocyte concentrations were significantly higher in both experimental groups compared with the sham group (P < .001). Ilomastat significantly attenuated the extent of lung inflammation and injury induced by both I/R and OA.
CONCLUSION:
MMP may play a critical role in the lung injury induced by I/R and OA infusion.
AuthorsD Y Yeh, H I Lin, N H Feng, C F Chen, D Wang, N T Wang
JournalTransplantation proceedings (Transplant Proc) Vol. 41 Issue 5 Pg. 1508-11 (Jun 2009) ISSN: 1873-2623 [Electronic] United States
PMID19545667 (Publication Type: Journal Article)
Chemical References
  • Enzyme Inhibitors
  • Hydroxamic Acids
  • Indoles
  • Matrix Metalloproteinase Inhibitors
  • RNA, Messenger
  • Oleic Acid
  • Hydroxyl Radical
  • Matrix Metalloproteinase 9
  • ilomastat
Topics
  • Animals
  • Enzyme Inhibitors (therapeutic use)
  • Femoral Vein (drug effects, physiology)
  • Hydroxamic Acids
  • Hydroxyl Radical (metabolism)
  • Indoles (therapeutic use)
  • Leukocyte Count
  • Lung (anatomy & histology, drug effects)
  • Lung Injury (prevention & control)
  • Male
  • Matrix Metalloproteinase 9 (genetics)
  • Matrix Metalloproteinase Inhibitors
  • Oleic Acid (toxicity)
  • Organ Size (drug effects)
  • Polymerase Chain Reaction
  • Pulmonary Artery (drug effects, physiology)
  • RNA, Messenger (drug effects, genetics)
  • Rats
  • Rats, Sprague-Dawley
  • Reperfusion
  • Reperfusion Injury (prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: